A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates
Donald A. Berry(Berry & Associates (United States)), Chi Heem Wong(Massachusetts Institute of Technology), Leah Isakov(Seqirus (United States)), Kien Wei Siah(Massachusetts Institute of Technology), Scott Berry(Queen's University), Andrew W. Lo(Massachusetts Institute of Technology), Peter Hale(Foundation for Vaccine Research)
Cited by 28
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818